Search results
cellular carcinoma represents about 90% of primary liver can-cers and constitutes a major global health problem. The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocel-lular carcinoma, as well as providing an in-depth review of all
This document presents official recommendations of the American Association for the Study of Liver Diseases (AASLD) on the surveillance, diagnosis, and treatment of hepatocellular carcinoma (HCC) occur-ring in the setting of adults with cirrhosis.
This guidance provides a data-supported approach to the diagnosis, staging, and treatment of patients diag-nosed with hepatocellular carcinoma (HCC). A guid-ance document is different from a guideline.
hepatocellular carcinoma. Key content includes diagnostic criteria, staging of disease, treatment plans and follow-up. The ESMO CPGs are intended to provide you with a set of recommendations for the best standards of care, using evidence-based medicine.
31 sty 2019 · Hepatocellular carcinoma: ESMO Clinical Practice † Guidelines for diagnosis, treatment and follow-up. *Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, 6900 Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org. †Approved by the ESMO Guidelines Committee: August 2018.
Abstract. Background. Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, including Australia. The absence of a consensus clinical practice guideline (CPG) specific to HCC management poses challenges in reducing morbidity, mortality, and improving patient recovery.
Early diagnosis of hepa-tocellular carcinoma remains a key goal in improving the poor prognosis of this form of liver cancer. Identify-ing hepatocellular carcinoma at an early stage is often associated with having better treatment options for pa-tients with small, asymptomatic tumors.
